Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study

J. Mascarenhas, E. Virtgaym, M. Stal, H. Blacklock, A. T. Gerds, Ruben Mesa, P. Ganly, D. Snyder, I. Tabbara, D. Tremblay, E. Moshier

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Myelofibrosis (MF) is a chronic yet progressive myeloid neoplasm in which only a minority of patients undergo curative therapy, hematopoietic stem cell transplantation. Ruxolitinib, a JAK1/2 inhibitor, is the lone therapy approved for MF, offering a clear symptom and spleen benefit at the expense of treatment-related cytopenias. Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression. Due to an FDA-mandated full clinical hold, the randomized phase 3 PERSIST trials were abruptly stopped and PAC was immediately discontinued for all patients. Thirty-three patients benefitting from PAC on clinical trial prior to the hold were allowed to resume therapy on an individual, compassionate-use basis. This study reports the detailed outcomes of 19 of these PAC retreatment patients with a median follow-up of 8 months. Despite a median platelet count of 49 × 109/L at restart of PAC, no significant change in hematologic profile was observed. Grade 3/4 adverse events of epistaxis (n = 1), asymptomatic QT prolongation (n = 1), and bradycardia (n = 1) occurred in three patients within the first 3 months of retreatment. One death due to catheter-associated sepsis occurred. The median time to discontinuation of PAC therapy on compassionate use for all 33 patients was 12.2 (95% CI 8.3—NR) months. PAC retreatment was associated with modest improvement in splenomegaly without progressive myelosuppression and supports the continued development of this agent for the treatment of MF second line to ruxolitinib or in the setting of treatment-limiting thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)1369-1374
Number of pages6
JournalAnnals of Hematology
Volume97
Issue number8
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Compassionate Use Trials
Primary Myelofibrosis
Retreatment
Therapeutics
Epistaxis
Hematopoietic Stem Cell Transplantation
Splenomegaly
Bradycardia
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
Platelet Count
Thrombocytopenia
Sepsis
Phosphotransferases
Spleen
Catheters
Clinical Trials

Keywords

  • JAK inhibitor
  • Myelofibrosis
  • Pacritinib

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes of patients with myelofibrosis treated with compassionate use pacritinib : a sponsor-independent international study. / Mascarenhas, J.; Virtgaym, E.; Stal, M.; Blacklock, H.; Gerds, A. T.; Mesa, Ruben; Ganly, P.; Snyder, D.; Tabbara, I.; Tremblay, D.; Moshier, E.

In: Annals of Hematology, Vol. 97, No. 8, 01.08.2018, p. 1369-1374.

Research output: Contribution to journalArticle

Mascarenhas, J, Virtgaym, E, Stal, M, Blacklock, H, Gerds, AT, Mesa, R, Ganly, P, Snyder, D, Tabbara, I, Tremblay, D & Moshier, E 2018, 'Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study', Annals of Hematology, vol. 97, no. 8, pp. 1369-1374. https://doi.org/10.1007/s00277-018-3309-6
Mascarenhas, J. ; Virtgaym, E. ; Stal, M. ; Blacklock, H. ; Gerds, A. T. ; Mesa, Ruben ; Ganly, P. ; Snyder, D. ; Tabbara, I. ; Tremblay, D. ; Moshier, E. / Outcomes of patients with myelofibrosis treated with compassionate use pacritinib : a sponsor-independent international study. In: Annals of Hematology. 2018 ; Vol. 97, No. 8. pp. 1369-1374.
@article{6168a6355f3b4b87959d55ff5f2ae074,
title = "Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study",
abstract = "Myelofibrosis (MF) is a chronic yet progressive myeloid neoplasm in which only a minority of patients undergo curative therapy, hematopoietic stem cell transplantation. Ruxolitinib, a JAK1/2 inhibitor, is the lone therapy approved for MF, offering a clear symptom and spleen benefit at the expense of treatment-related cytopenias. Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression. Due to an FDA-mandated full clinical hold, the randomized phase 3 PERSIST trials were abruptly stopped and PAC was immediately discontinued for all patients. Thirty-three patients benefitting from PAC on clinical trial prior to the hold were allowed to resume therapy on an individual, compassionate-use basis. This study reports the detailed outcomes of 19 of these PAC retreatment patients with a median follow-up of 8 months. Despite a median platelet count of 49 × 109/L at restart of PAC, no significant change in hematologic profile was observed. Grade 3/4 adverse events of epistaxis (n = 1), asymptomatic QT prolongation (n = 1), and bradycardia (n = 1) occurred in three patients within the first 3 months of retreatment. One death due to catheter-associated sepsis occurred. The median time to discontinuation of PAC therapy on compassionate use for all 33 patients was 12.2 (95{\%} CI 8.3—NR) months. PAC retreatment was associated with modest improvement in splenomegaly without progressive myelosuppression and supports the continued development of this agent for the treatment of MF second line to ruxolitinib or in the setting of treatment-limiting thrombocytopenia.",
keywords = "JAK inhibitor, Myelofibrosis, Pacritinib",
author = "J. Mascarenhas and E. Virtgaym and M. Stal and H. Blacklock and Gerds, {A. T.} and Ruben Mesa and P. Ganly and D. Snyder and I. Tabbara and D. Tremblay and E. Moshier",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s00277-018-3309-6",
language = "English (US)",
volume = "97",
pages = "1369--1374",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Outcomes of patients with myelofibrosis treated with compassionate use pacritinib

T2 - a sponsor-independent international study

AU - Mascarenhas, J.

AU - Virtgaym, E.

AU - Stal, M.

AU - Blacklock, H.

AU - Gerds, A. T.

AU - Mesa, Ruben

AU - Ganly, P.

AU - Snyder, D.

AU - Tabbara, I.

AU - Tremblay, D.

AU - Moshier, E.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Myelofibrosis (MF) is a chronic yet progressive myeloid neoplasm in which only a minority of patients undergo curative therapy, hematopoietic stem cell transplantation. Ruxolitinib, a JAK1/2 inhibitor, is the lone therapy approved for MF, offering a clear symptom and spleen benefit at the expense of treatment-related cytopenias. Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression. Due to an FDA-mandated full clinical hold, the randomized phase 3 PERSIST trials were abruptly stopped and PAC was immediately discontinued for all patients. Thirty-three patients benefitting from PAC on clinical trial prior to the hold were allowed to resume therapy on an individual, compassionate-use basis. This study reports the detailed outcomes of 19 of these PAC retreatment patients with a median follow-up of 8 months. Despite a median platelet count of 49 × 109/L at restart of PAC, no significant change in hematologic profile was observed. Grade 3/4 adverse events of epistaxis (n = 1), asymptomatic QT prolongation (n = 1), and bradycardia (n = 1) occurred in three patients within the first 3 months of retreatment. One death due to catheter-associated sepsis occurred. The median time to discontinuation of PAC therapy on compassionate use for all 33 patients was 12.2 (95% CI 8.3—NR) months. PAC retreatment was associated with modest improvement in splenomegaly without progressive myelosuppression and supports the continued development of this agent for the treatment of MF second line to ruxolitinib or in the setting of treatment-limiting thrombocytopenia.

AB - Myelofibrosis (MF) is a chronic yet progressive myeloid neoplasm in which only a minority of patients undergo curative therapy, hematopoietic stem cell transplantation. Ruxolitinib, a JAK1/2 inhibitor, is the lone therapy approved for MF, offering a clear symptom and spleen benefit at the expense of treatment-related cytopenias. Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression. Due to an FDA-mandated full clinical hold, the randomized phase 3 PERSIST trials were abruptly stopped and PAC was immediately discontinued for all patients. Thirty-three patients benefitting from PAC on clinical trial prior to the hold were allowed to resume therapy on an individual, compassionate-use basis. This study reports the detailed outcomes of 19 of these PAC retreatment patients with a median follow-up of 8 months. Despite a median platelet count of 49 × 109/L at restart of PAC, no significant change in hematologic profile was observed. Grade 3/4 adverse events of epistaxis (n = 1), asymptomatic QT prolongation (n = 1), and bradycardia (n = 1) occurred in three patients within the first 3 months of retreatment. One death due to catheter-associated sepsis occurred. The median time to discontinuation of PAC therapy on compassionate use for all 33 patients was 12.2 (95% CI 8.3—NR) months. PAC retreatment was associated with modest improvement in splenomegaly without progressive myelosuppression and supports the continued development of this agent for the treatment of MF second line to ruxolitinib or in the setting of treatment-limiting thrombocytopenia.

KW - JAK inhibitor

KW - Myelofibrosis

KW - Pacritinib

UR - http://www.scopus.com/inward/record.url?scp=85044786406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044786406&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3309-6

DO - 10.1007/s00277-018-3309-6

M3 - Article

C2 - 29616317

AN - SCOPUS:85044786406

VL - 97

SP - 1369

EP - 1374

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 8

ER -